NCT04416633View on ClinicalTrials.gov

Study to Access Safety of Durvalumab in Indian Adult Patients With Locally Advanced NSCLC

PHASE4CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

November 30, 2021

Primary Completion Date

October 27, 2023

Study Completion Date

October 27, 2023

Conditions
Unresectable Non-small Cell Lung Cancer (NSCLC)
Interventions
DRUG

Durvalumab

500-mg/120-mg IV

Trial Locations (12)

110005

Research Site, New Delhi

110029

Research Site, Delhi

110085

Research Site, Delhi

121001

Research Site, Faridabad

122001

Research Site, Gūrgaon

160055

Research Site, Mohali

400012

Research Site, Mumbai

400053

Research Site, Mumbai

400056

Research Site, Mumbai

560017

Research Site, Bangalore

560022

Research Site, Bangalore

700160

Research Site, Kolkata

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY